NCT00064246View on ClinicalTrials.gov

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

September 30, 2004

Conditions
Post-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaWaldenström Macroglobulinemia
Interventions
BIOLOGICAL

rituximab

Given IV

RADIATION

indium In 111 ibritumomab tiuxetan

Given IV

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Given IV

Trial Locations (1)

20850

AIDS - Associated Malignancies Clinical Trials Consortium, Rockville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00064246 - Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | Biotech Hunter | Biotech Hunter